	Numb r: 09/34, 965 Changed a file from non-ASCII to ASCII ENTERED
	·
	Changed the margins in cases where the sequence text was "wrapped" down to the next line.
	Edited a format error in the Current Application Data section, specifically:
	Edited the Current Application Data section with the actual current number. The number inputted by the applicant was the prior application data; or other
	Added the mandatory heading and subheadings for "Current Application Data".
	Edited the "Number of Sequences" (ield. The applicant spelled out a number instead of using an integer
	Changed the spelling of a mandatory field (the headings or subheadings), specifically:
	Corrected the SEQ ID NO when obviously incorrect. The sequence numbers that were edited were:
	Inserted or corrected a nucleic number at the end of a nucleic line. SEQ ID NO's edited:
	Corrected subheading placement. All responses must be on the same line as each subheading. If the applicant placed a response below the subheading, this was moved to its appropriate place.
	Inserted colons after headings/subheadings. Headings edited included:
	Deleted extra, invalid, headings used by an applicant, specifically:
	Deleted: non-ASCII "garbage" at the beginning/end of files; secretary initials/filename at end of the page numbers throughout text; other invalid text, such as extrangous material a
	Inserted mandatory headings, specifically: $\underline{\hspace{1cm}}$
	Corrected an obvious error in the response, specifically:
	Edited identifiers where upper case is used but lower case is required, or vice versa.
	Corrected an error in the Number of Sequences field, specifically:
	A "Hard Page Break" code was inserted by the applicant. All occurrences had to be deleted.
2	Deleted ending stop codon in amino acid sequences and adjusted the *(A)Length:* field accordingly (errough to a Patentin bug). Sequences corrected:
	Other:
-	
	\

^{*}Examiner: The above corrections must be communicated to the applicant in the first Office Action. DO NOT send a copy of this form.

1644

```
Input Set : A:\Cpg.pto
                     Output Set: N:\CRF3\11022000\I434965.raw
                     SEQUENCE LISTING
      4 (1) GENERAL INFORMATION:
             (i) APPLICANT: Luxembourg, Alain T.
                            Jackson, Michael R.
      Я
                            Peterson, Per A.
     10
            (ii) TITLE OF INVENTION: PURIFICATION OF ANTIGEN-SPECIFIC T CELLS
           (iii) NUMBER OF SEQUENCES: 11
     1.2
            (iv) CORRESPONDENCE ADDRESS:
     14
     15
                  (A) ADDRESSEE: Johnson & Johnson
     16
                  (B) STREET: One Johnson & Johnson Plaza
     17
                  (C) CITY: New Brunswick
     18
                  (D) STATE: NJ
     19
                  (E) COUNTRY: USA
     20
                  (F) ZIP: 08933-7003
             (V) COMPUTER READABLE FORM:
     22
     23
                  (A) MEDIUM TYPE: Floppy disk
     24
                  (B) COMPUTER: IBM PC compatible
     25
                  (C) OPERATING SYSTEM: PC-DOS/MS-DOS
     26
                  (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
     28
            (vi) CURRENT APPLICATION DATA:
C--> 29
                  (A) APPLICATION NUMBER: US/09/434,965
    30
                  (B) FILING DATE: 05-Nov-1999
     31
                  (C) CLASSIFICATION:
     33
          (viii) ATTORNEY/AGENT INFORMATION:
     34
                  (A) NAME: Wallen, John W.
     35
                  (B) REGISTRATION NUMBER: 35,403
     36
                  (C) REFERENCE/DOCKET NUMBER: ORT-841
     38
            (ix) TELECOMMUNICATION INFORMATION:
     39
                  (A) TELEPHONE: 732-524-2806
     40
                  (B) TELEFAX: 732-524-2808
       (2) INFORMATION FOR SEQ ID NO: 1:
     45
             (i) SEQUENCE CHARACTERISTICS:
     47
     48
                  (A) LENGTH: 9 amino acids
                  (B) TYPE: amino acid
     49
                  (C) STRANDEDNESS: single
     50
     51
                  (D) TOPOLOGY: linear
     53
            (ii) MOLECULE TYPE: peptide
     55
            (iv) ANTI-SENSE: NO
     57
            (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
            Gln Leu Ser Pro Phe Pro Phe Asp Leu
     59
     60
     63 (2) INFORMATION FOR SEQ ID NO: 2:
             (i) SEQUENCE CHARACTERISTICS:
     65
     66
                  (A) LENGTH: 8 amino acids
                  (B) TYPE: amino acid
     68
                  (C) STRANDEDNESS: single
                  (D) TOPOLOGY: linear
```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/434,965

DATE: 11/02/2000

TIME: 12:37:24

RAW SEQUENCE LISTING

DATE: 11/02/2000

PATENT APPLICATION: US/09/434,965

TIME: 12:37:24

Input Set : A:\Cpg.pto

Output Set: N:\CRF3\11022000\I434965.raw

```
(ii) MOLECULE TYPE: peptide
71
       (iv) ANTI-SENSE: NO
73
75
       (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
        Leu Ser Pro Phe Pro Phe Asp Leu
77
                         5
78
81 (2) INFORMATION FOR SEQ ID NO: 3:
        (i) SEQUENCE CHARACTERISTICS:
84
             (A) LENGTH: 9 amino acids
             (B) TYPE: amino acid
85
             (C) STRANDEDNESS: single
86
87
             (D) TOPOLOGY: linear
       (ii) MOLECULE TYPE: peptide
89
       (iv) ANTI-SENSE: NO
9.1
93
       (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
96
        Ser Pro Phe Pro Phe Asp Leu Leu Leu
97
100 (2) INFORMATION FOR SEQ ID NO: 4:
         (i) SEQUENCE CHARACTERISTICS:
1.03
              (A) LENGTH: 8 amino acids
              (B) TYPE: amino acid
104
              (C) STRANDEDNESS: single
105
1.06
              (D) TOPOLOGY: Linear
        (ii) MOLECULE TYPE: peptide
1.08
        (iv) ANTI-SENSE: NO
110
112
        (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
         Leu Ser Ala Phe Pro Phe Asp Leu
1. 5
1.15
118 (2) INFORMATION FOR SEQ ID NO: 5:
1.20
         (i) SEQUENCE CHARACTERISTICS:
121
              (A) LENGTH: 8 amino acids
              (B) TYPE: amino acid
1.22
              (C) STRANDEDNESS: single
1.23
124
              (D) TOPOLOGY: linear
        (ii) MOLECULE TYPE: peptide
126
        (iv) ANTI-SENSE: NO
128
        (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
130
132
         Glu Gln Tyr Lys Phe Tyr Ser Val
133
                         5
136 (2) INFORMATION FOR SEQ ID NO: 6:
         (i) SEQUENCE CHARACTERISTICS:
138
139
              (A) LENGTH: 8 amino acids
              (B) TYPE: amino acid
140
              (C) STRANDEDNESS: single (D) TOPOLOGY: linear
141
1.42
144
        (ii) MOLECULE TYPE: peptide
        (iv) ANTI-SENSE: NO
        (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
149
         Ser Tle Tyr Arg Tyr Tyr Gly Leu
1 5
1.51
152
```

RAW SEQUENCE LISTING

DATE: 11/02/2000 TIME: 12:37:24

PATENT APPLICATION: US/09/434,965

Input Set : A:\Cpg.pto

Output Set: N:\CRF3\11022000\1434965.raw

```
155 (2) INFORMATION FOR SEQ ID NO: 7:
         (i) SEQUENCE CHARACTERISTICS:
157
              (A) LENGTH: 9 amino acids
158
159
              (B) TYPE: amino acid
              (C) STRANDEDNESS: single
160
              (D) TOPOLOGY: linear
161
163
        (ii) MOLECULE TYPE: peptide
165
        (iv) ANTI-SENSE: NO
        (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
167
169
         Arg Pro Gln Ala Ser Gly Val Tyr Met
170
173 (2) INFORMATION FOR SEQ ID NO: 8:
         (i) SEQUENCE CHARACTERISTICS:
175
              (A) LENGTH: 9 amino acids
176
              (B) TYPE: amino acid
177
178
              (C) STRANDEDNESS: single
              (D) TOPOLOGY: linear
179
        (ii) MOLECULE TYPE: peptide
181
        (iv) ANTI-SENSE: NO
183
        (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
185
         Tyr Pro His Phe Met Pro Thr Asn Leu
187
188
                         5
190 (2) INFORMATION FOR SEQ ID NO: 9:
         (i) SEQUENCE CHARACTERISTICS:
192
              (A) LENGTH: 8 amino acids
193
1.94
              (B) TYPE: amino acid
1.95
              (C) STRANDEDNESS: single
              (D) TOPOLOGY: linear
1.96
198
        (ii) MOLECULE TYPE: peptide
200
        (iv) ANTI-SENSE: NO
        (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
204
         Ser Ile Ile Asn Phe Glu Lys Leu
205
                         5
208 (2) INFORMATION FOR SEQ ID NO: 10:
         (i) SEQUENCE CHARACTERISTICS:
211
              (A) LENGTH: 8 amino acids
              (B) TYPE: amino acid
212
213
              (C) STRANDEDNESS: single
              (D) TOPOLOGY: linear
214
216
        (ii) MOLECULE TYPE: peptide
        (iv) ANTI-SENSE: NO
218
220
        (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
         \hbox{Arg Gly Tyr Val Tyr Gln Gly Asn} 
222
223
226 (2) INFORMATION FOR SEQ ID NO: 11:
228
         (i) SEQUENCE CHARACTERISTICS:
              (A) LENGTH: 8 amino acids
              (B) TYPE: amino acid
230
              (C) STRANDEDNESS: single
231
```

DATE: 11/02/2000 TIME: 12:37:24

RAW SEQUENCE LISTING PATENT APPLICATION: US/09/434,965

Input Set : A:\Cpg.pto
Output Set: N:\CRF3\11022000\I434965.raw

232	(D) TOPOLOGY: linear
234	(ii) MOLECULE TYPE: peptide
236	(iv) ANTI-SENSE: NO
238	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
240	Glu Ile Ile Asn Phe Glu Lys Leu
241	1 5

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/434,965

DATE: 11/02/2000 TIME: 12:37:25

Input Set : A:\Cpg.pto
Output Set: N:\CRF3\11022000\1434965.raw

L:29 M:220 C: Keyword misspelled or invalid format, [(A) APPLICATION NUMBER:] L:30 M:220 C: Keyword misspelled or invalid format, [(B) FILING DATE:]